Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1999-3-4
|
pubmed:abstractText |
The effects of topical betamethasone-17-valerate on collagen propeptide levels, collagen mRNA level, lysyl oxidase mRNA and matrix metalloproteinase (MMP)-1 and MMP-2 mRNA levels were studied in human skin. Three days' treatment of healthy skin with topical betamethasone caused a 70-80% decrease in type I and III collagen propeptides in suction blister fluid. A similar decrease was found in type I collagen mRNA when assayed by either slot-blot hybridization or a quantitative polymerase chain reaction method, indicating that the decrease in collagen synthesis after topical glucocorticoid treatment is apparently due to a decrease in corresponding mRNA. mRNA of lysyl oxidase, which is an important enzyme catalysing the cross-linking of collagen chains, and collagen-degrading enzyme MMP-1 and MMP-2 mRNAs were not decreased in the same skin samples. This suggests that in vivo, glucocorticoids modulate variably the genes involved in collagen synthesis and degradation. Our study provides a solid molecular basis for glucocorticoid-induced dermal atrophy, which results from the decrease in functional collagen mRNA in the skin.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Betamethasone 17-Valerate,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen,
http://linkedlifedata.com/resource/pubmed/chemical/Collagenases,
http://linkedlifedata.com/resource/pubmed/chemical/Gelatinases,
http://linkedlifedata.com/resource/pubmed/chemical/Glucocorticoids,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 1,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Metalloendopeptidases,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0007-0963
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
139
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1106-10
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9990383-Administration, Topical,
pubmed-meshheading:9990383-Adult,
pubmed-meshheading:9990383-Anti-Inflammatory Agents,
pubmed-meshheading:9990383-Atrophy,
pubmed-meshheading:9990383-Betamethasone 17-Valerate,
pubmed-meshheading:9990383-Collagen,
pubmed-meshheading:9990383-Collagenases,
pubmed-meshheading:9990383-Gelatinases,
pubmed-meshheading:9990383-Glucocorticoids,
pubmed-meshheading:9990383-Humans,
pubmed-meshheading:9990383-Male,
pubmed-meshheading:9990383-Matrix Metalloproteinase 1,
pubmed-meshheading:9990383-Matrix Metalloproteinase 2,
pubmed-meshheading:9990383-Metalloendopeptidases,
pubmed-meshheading:9990383-RNA, Messenger,
pubmed-meshheading:9990383-Skin
|
pubmed:year |
1998
|
pubmed:articleTitle |
The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo.
|
pubmed:affiliation |
Department of Dermatology, Oulu University Hospital, Finland. aarne.oikarinen@oulu.fi
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|